Expert Opinion on Orphan Drugs

metrics 2024

Transforming challenges into solutions for rare diseases.

Introduction

Expert Opinion on Orphan Drugs is a pivotal academic journal published by Taylor & Francis Ltd, focusing on the burgeoning field of orphan drugs, which are often essential for treating rare diseases. As an integral source of insights and advancements from 2013 to 2024, this journal aims to bridge the gap between emerging scientific research and clinical application, providing a platform for authors to discuss pharmacological innovations and policy implications. With its ISSN 2167-8707, the journal has established a reputably rigorous editorial process and is indexed in Scopus, showcasing its relevance with ranks in various pharmacology and health policy disciplines. Though currently not an open-access journal, it endeavors to deliver high-quality articles that are vital for researchers, healthcare professionals, and policy makers aiming to navigate the complexities and challenges in the orphan drug landscape. It is categorized in Q4 for Health Policy and Q3 for Pharmacology in recent evaluations, reflecting its accessible yet scholarly contributions to this niche area of medical research.

Metrics 2024

SCIMAGO Journal Rank0.20
Journal Impact Factor0.80
Journal Impact Factor (5 years)0.70
H-Index27
Journal IF Without Self0.80
Eigen Factor0.00
Normal Eigen Factor0.09
Influence0.27
Immediacy Index0.10
Cited Half Life7.00
Citing Half Life9.40
JCI0.14
Total Documents799
WOS Total Citations339
SCIMAGO Total Citations1625
SCIMAGO SELF Citations63
Scopus Journal Rank0.20
Cites / Document (2 Years)0.86
Cites / Document (3 Years)0.78
Cites / Document (4 Years)0.75

Metrics History

Rank 2024

Scopus

Pharmacology, Toxicology and Pharmaceutics (miscellaneous) in Pharmacology, Toxicology and Pharmaceutics
Rank #14/43
Percentile 67.44
Quartile Q2
Health Policy in Medicine
Rank #183/310
Percentile 40.97
Quartile Q3
Pharmacology (medical) in Medicine
Rank #173/272
Percentile 36.40
Quartile Q3

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 311/354
Percentile 12.30
Quartile Q4

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 330/354
Percentile 6.78
Quartile Q4

Quartile History

Similar Journals

MEDICAL LETTER ON DRUGS AND THERAPEUTICS

Your Resource for Cutting-Edge Therapeutic Developments
Publisher: MED LETTER INCISSN: 0025-732XFrequency: 26 issues/year

MEDICAL LETTER ON DRUGS AND THERAPEUTICS is a pivotal resource for professionals in the fields of medicine and pharmacology, published by MED LETTER INC. Since its inception in 1965, this journal has been committed to elucidating the complexities of drug therapy and clinical therapeutics, offering readers evidence-based insights and critical evaluations of the latest medications and treatment protocols. With a quarterly ranking reflecting its stature—Q4 in Medicine (Miscellaneous) and Q3 in both Pharmacology and Pharmacology (Medical)—the journal maintains a specific niche ensuring readers are equipped with updated information that continues to influence healthcare practices. Although it does not operate under an open access model, the journal is accessible to institutions and professionals eager to stay at the forefront of medicinal advancements. The importance of this journal lies in its dedication to enhancing pharmacological knowledge, thus catering to the needs of researchers, healthcare providers, and students alike, making it an essential addition to the literature in therapeutic drug interventions.

ANNALS OF CLINICAL AND LABORATORY SCIENCE

Advancing Knowledge in Clinical and Laboratory Sciences
Publisher: ASSOC CLINICAL SCIENTISTSISSN: 0091-7370Frequency: 6 issues/year

ANNALS OF CLINICAL AND LABORATORY SCIENCE, published by the Association of Clinical Scientists, is a pivotal journal in the fields of clinical biochemistry, hematology, immunology, and medical laboratory technology. Since its inception in 1971, this journal has become a vital resource for researchers and practitioners aiming to advance their knowledge and skills in laboratory sciences. Although currently not an open access journal, its rich repository of peer-reviewed articles and studies contributes significantly to the academic discourse in diagnostic and therapeutic practices. The journal is categorized in various quartiles, reflecting its impact and contributions to multiple scientific domains, such as Q4 in Clinical Biochemistry and Q3 in Pathology and Forensic Medicine as of 2023. With an extensive convergence of years up to 2024, it proves to be a timeless source for emerging trends and research innovations. The ANNALS OF CLINICAL AND LABORATORY SCIENCE not only supports the professional development of its readers but also encourages interdisciplinary collaboration, making it an essential tool for professionals, students, and researchers dedicated to improving health outcomes through advanced laboratory sciences.

RHEUMATOLOGY INTERNATIONAL

Empowering researchers and clinicians with vital insights.
Publisher: SPRINGER HEIDELBERGISSN: 0172-8172Frequency: 12 issues/year

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

ORVOSI HETILAP

Navigating the Future of General Medicine
Publisher: AKADEMIAI KIADO ZRTISSN: 0030-6002Frequency: 52 issues/year

ORVOSI HETILAP is a pivotal journal in the field of general medicine, published by AKADEMIAI KIADO ZRT in Hungary. With its rich history dating back to 1949, this journal has been a platform for disseminating significant research findings and clinical advancements that impact healthcare practices. Although it currently falls within the Q4 category in the 2023 ranking of Medicine (miscellaneous), it holds a Scopus rank of #320 among 636 journals in its category, indicating its growing recognition among peers and scholars. The journal does not offer open access options, which may limit broader dissemination, but it nonetheless remains an important resource for medical professionals, researchers, and students engaging with contemporary medical issues. Located in the vibrant academic landscape of Budapest, ORVOSI HETILAP continues to contribute to the evolving dialogue in the medical community, showcasing diverse topics and fostering interdisciplinary collaboration.

Rare Tumors

Empowering insights on rare tumor challenges.
Publisher: SAGE PUBLICATIONS LTDISSN: 2036-3605Frequency: 1 issue/year

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

Internal Medicine

Contributing to the Future of Internal Medicine
Publisher: JAPAN SOC INTERNAL MEDICINEISSN: 0918-2918Frequency: 12 issues/year

Internal Medicine is a distinguished peer-reviewed journal published by the Japan Society of Internal Medicine, focusing on the nuanced field of internal medicine. Since its inception in 1974 and with a commitment to advancing medical knowledge, the journal has evolved remarkably, aiming to disseminate high-quality research that contributes to the understanding and treatment of internal diseases. Operating from Tokyo, Japan, it provides an intellectual platform for researchers and clinicians to publish original articles, reviews, and case studies that address various aspects of internal medicine. The journal currently holds a ranking in the Q3 quartile for both Internal Medicine and miscellaneous Medicine categories as of 2023, signifying its growing influence in the medical community. Although not an open-access journal, it remains accessible to a wide audience through institutional subscriptions, enhancing its reach among professionals and students alike. With its commitment to excellence, Internal Medicine serves as an essential resource for those seeking the latest developments and research within this vital medical field.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pioneering Insights for Digestive Health Innovations
Publisher: WILEYISSN: 0269-2813Frequency: 24 issues/year

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

Current Rheumatology Reviews

Empowering researchers with comprehensive rheumatology insights.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-3971Frequency: 3 issues/year

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

AKTUELLE RHEUMATOLOGIE

Shaping the future of rheumatology with impactful studies.
Publisher: GEORG THIEME VERLAG KGISSN: 0341-051XFrequency: 6 issues/year

AKTUELLE RHEUMATOLOGIE is a prominent German journal published by GEORG THIEME VERLAG KG, dedicated to advancing the field of rheumatology. Since its inception in 1978, this peer-reviewed journal has been a vital resource for professionals, researchers, and students engaged in the study and treatment of rheumatic diseases. With an ISSN of 0341-051X and an E-ISSN of 1438-9940, the journal provides a platform for sharing groundbreaking research, clinical studies, and reviews. Although classified in the fourth quartile (Q4) of rheumatology journals and ranked 67 out of 73 in its category according to Scopus, AKTUELLE RHEUMATOLOGIE continues to contribute to the discourse in rheumatology. Its comprehensive coverage of recent advancements and innovative approaches makes it an essential publication for anyone interested in the latest developments in the field.

DRUGS & THERAPY PERSPECTIVES

Empowering Researchers and Practitioners in Drug Therapy
Publisher: SPRINGERNATUREISSN: 1172-0360Frequency: 12 issues/year

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.